about
Pharmacological interventions for reducing weight gain in schizophreniaBehavioural interventions for reducing weight gain in schizophreniaAntipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problemsAntipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problemsTreating Negative Symptoms in Schizophrenia: an UpdateAntipsychotic Polypharmacy and Corrected QT Interval: A Systematic ReviewNeuroimaging findings in treatment-resistant schizophrenia: A systematic review: Lack of neuroimaging correlates of treatment-resistant schizophreniaEstimated dopamine D₂ receptor occupancy and remission in schizophrenia: analysis of the CATIE data.Estimated dopamine D2 receptor occupancy from plasma concentrations of atypical antipsychotics and subjective experience/drug attitude in schizophrenia: an analysis of the CATIE data.Clinical determinants of life satisfaction in chronic schizophrenia: data from the CATIE study.Tardive dyskinesia in relation to estimated dopamine D2 receptor occupancy in patients with schizophrenia: analysis of the CATIE data.Impact of once- versus twice-daily perphenazine dosing on clinical outcomes: an analysis of the CATIE data.Glutamate-mediated excitotoxicity in schizophrenia: a review.Comparative efficacy between clozapine and other atypical antipsychotics on depressive symptoms in patients with schizophrenia: analysis of the CATIE phase 2E data.Effect of antipsychotic pharmacotherapy on clinical outcomes of intermittent theta-burst stimulation for refractory depression.The Effect of Clozapine on Hematological Indices: A 1-Year Follow-Up Study.Negative symptoms in schizophrenia: avolition and Occam's razorAn algorithm-based approach to first-episode schizophrenia: response rates over 3 prospective antipsychotic trials with a retrospective data analysis.Antipsychotic dosing: how much but also how often?Interpreting a multivariate analysis of functional neuroimaging data.Topiramate in schizophrenia: a review of effects on psychopathology and metabolic parameters.Atypical antipsychotics and effects of adrenergic and serotonergic receptor binding on insulin secretion in-vivo: an animal model.Estimating endogenous dopamine levels at D2 and D3 receptors in humans using the agonist radiotracer [(11)C]-(+)-PHNOTardive dyskinesia: eliminated, forgotten, or overshadowed?The vacuous chewing movement (VCM) model of tardive dyskinesia revisited: is there a relationship to dopamine D(2) receptor occupancy?Prediction of brain clozapine and norclozapine concentrations in humans from a scaled pharmacokinetic model for rat brain and plasma pharmacokineticsInvestigational drugs for schizophrenia targeting the dopamine receptor: phase II trials.Illness denial in schizophrenia spectrum disorders: a function of left hemisphere dominanceReview: amisulpride is effective and safe for schizophrenia.Targeting the dopamine receptor in schizophrenia: investigational drugs in Phase III trials.Actigraphic measurement of the effects of single-dose haloperidol and olanzapine on spontaneous motor activity in normal subjects.Understanding antipsychotic "atypicality": a clinical and pharmacological moving targetAntipsychotics and amotivationImpaired insight into illness and cognitive insight in schizophrenia spectrum disorders: resting state functional connectivityThe VAGUS insight into psychosis scale--self-report and clinician-rated versions.The use of pharmacotherapy in the prodrome of schizophrenia.Reduced insulin sensitivity is related to less endogenous dopamine at D2/3 receptors in the ventral striatum of healthy nonobese humansPredictors and markers of clozapine response.Recent advances in understanding and mitigating adipogenic and metabolic effects of antipsychotic drugs.Physical activity preferences of individuals diagnosed with schizophrenia or bipolar disorder
P50
Q24194410-3472BA73-4DA6-4CD3-AEBA-25EFD84F7588Q24197824-DA7BA4DA-9705-43EE-8767-2F5B087E505AQ24235450-BD53574E-51B7-4AA6-8501-49E0C72EA1D8Q24244736-60E22C97-CB8F-4702-BAC2-AFA3D58A034BQ26744805-965F6511-CC14-4C07-B0C1-2B8D015AF30BQ26801835-6192C4A8-A06E-40BE-B662-05920BC7DDD1Q27026382-32E04CEF-62D6-4C84-A92D-B54034CE9FBBQ30658234-2CEF63C1-44EE-43E0-9A23-9C25764A0007Q30666489-51E6478F-53DD-4B4F-BF27-565024CAB9F2Q30687896-4711FF91-7B6E-43F8-BBFE-48C60FF72EC9Q30747608-845090AA-7D1D-4B7B-96E5-F6B06766837EQ30764477-FC827FCD-C559-4893-94E0-43D52EB7835FQ30845062-A5091134-128E-40E4-9B8C-08E1AF31F73EQ30882594-B3F2C862-E111-41A2-8975-D124192FF12BQ31142701-621D6B35-FA70-4F9C-B11B-84EFAFCCC67DQ33425143-B458EC1E-D526-4D27-94CD-5F675C02CBFAQ33707635-5D7E7E14-751F-4945-921D-F4E7E211B383Q33860571-8BF9A724-92AC-46C2-8F38-20704A501AB8Q34023214-51B47139-0D8C-4D6C-A80F-E82D03A309F1Q34290769-E9BA8FC7-652C-4CED-9900-BA87085E9F0FQ34321791-3E38847A-1A3F-43F0-BE4D-C1D0B930F12BQ34333332-F2E7BA4D-E3D9-443E-A587-F1AA9EA57554Q34356950-562A09FA-7E0A-47CC-9060-373E77ED88E8Q34574811-92EBF837-AD9F-4B8D-BE57-DC2292793C8BQ34659357-18F0F1E1-1909-46E0-949E-C64F74A87922Q34667775-BB5221A9-3526-4726-B68E-6C079B9946A4Q34703195-C89A2FF3-3025-4348-98C3-5EA872EB1E39Q34715809-971B241D-D42F-4EDF-AAE1-B69321E3396DQ34785846-4470A08E-9AB1-46AE-9A58-7C3BEC4DC6C9Q35071909-4A5125D1-7A19-4FA4-88A8-80DBD4891935Q35162561-E4229CFF-18E9-4C3B-84D3-FA2C102F19D6Q35200831-50C74F93-A488-4209-BC79-71F345D179EBQ35421296-30E21799-502A-4840-AF72-13E0FF39A66EQ35599817-1D7FF04C-FDC7-47EF-8E7C-AE114F865057Q35751647-A39E8FA6-0ADA-48F2-85D2-15F25D6D3692Q35845519-E9CD03C9-AC1E-4D73-814F-AEF48C393D5EQ35965889-55E83855-82DA-4D74-A217-FF0875CFF263Q36045493-A6E07FD0-097E-4AD4-8300-BA1D49EAD9C8Q36063735-6A8F93BC-7E36-4D3C-A62C-1DA8F73132FDQ36074188-D02ABA13-3D53-4B1D-AF9C-54D0575C3CC8
P50
name
Gary Remington
@en
Gary Remington
@nl
type
label
Gary Remington
@en
Gary Remington
@nl
prefLabel
Gary Remington
@en
Gary Remington
@nl